This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL (NCT04134936), a randomized phase 1 study. The primary outcome is Incidence and Severity of Treatment-emergent Adverse Events (TEAEs).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04134936 |
| Phase | Phase 1 |
| Condition | Diffuse Large B-cell Lymphoma |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 66 |
| Arms in the primary outcome | n/a |
| Lead sponsor | MorphoSys AG |
| Results posted | Yes |
2. Clinical Question
Population
Adults with newly diagnosed, previously untreated diffuse large B-cell lymphoma (DLBCL). The registry record describes 66 participants enrolled overall. The reported safety groups each list 33 participants at risk.
Intervention
Tafasitamab added to R-CHOP, or tafasitamab plus lenalidomide added to R-CHOP. R-CHOP comprises rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Comparator
The randomized parallel groups were Arm A, tafasitamab plus R-CHOP, and Arm B, tafasitamab plus lenalidomide plus R-CHOP. The study was open-label, with no masking.
Primary question
The primary endpoint was the incidence and severity of treatment-emergent adverse events (TEAEs), measured as participant counts over approximately 6 months. The registry also identifies preliminary efficacy as a study aim and lists response and time-to-event outcomes, but comparative efficacy analyses are not reported in the registry record.
The central statistical question is therefore about safety description: how many participants in each treatment group were recorded as having serious and other adverse events during the reported period, and how should those counts be interpreted? The record lists serious events in 14 participants in Arm A and 17 in Arm B, and other adverse events in 31 participants in Arm A and 32 in Arm B. These are descriptive counts. Without a posted comparative analysis, they do not establish whether the observed difference between groups is beyond what might occur through chance variation.
The question is also limited by the study’s early phase and stated focus on preliminary efficacy. The record does not report an efficacy estimate, confidence interval, or statistical test comparing the arms. The listed secondary outcomes include response rates, complete response, progression-free survival, event-free survival, and time to next anti-lymphoma treatment. Their inclusion identifies outcomes of interest, not evidence of a particular treatment effect.
3. Trial Design
NCT04134936, titled First-MIND, was a Phase Ib, randomized, open-label, multicentre, parallel-group study sponsored by MorphoSys AG. It enrolled adults with newly diagnosed, previously untreated DLBCL. The registry record gives an enrollment of 66, a start date of 2019-12-11, a primary completion date of 2021-02-11, and a status of completed.
Participants were assigned to one of two treatment groups. Arm A received tafasitamab in addition to R-CHOP. Arm B received tafasitamab plus lenalidomide in addition to R-CHOP. R-CHOP consists of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Since the study was open-label and had no masking, treatment assignment was not concealed from participants or study personnel according to the design description.
Randomization can help balance participant characteristics across groups on average, while a parallel-group design means the groups receive their respective regimens rather than crossing over between them as part of the described comparison. Those general design features do not guarantee that groups are identical, and they do not replace a reported statistical comparison. Although the safety records list 33 participants at risk in each arm, the registry record does not report the allocation ratio or further details of the randomization procedure.
The primary outcome was incidence and severity of TEAEs, measured as counts of participants over approximately 6 months. The record also lists 11 outcome measures, including outcomes for response at the end of treatment and through the end of study, complete response, adverse events during follow-up, progression-free survival at 12 and 24 months, event-free survival at 12 and 24 months, and time to next anti-lymphoma treatment. These listed outcomes do not by themselves provide their results or analysis methods. The registry record does not report the study’s sample-size justification or a detailed statistical analysis plan.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Arm A | Arm B |
|---|---|---|
| STARTED | 33 | 33 |
| COMPLETED | 26 | 27 |
| NOT COMPLETED | 7 | 6 |
Reasons for not completing this period:
| Reason | Arm A | Arm B |
|---|---|---|
| Adverse Event | 3 | 2 |
| Withdrawal by Subject | 2 | 3 |
| Physician Decision | 0 | 1 |
| Progressive disease, joined another trial | 1 | 0 |
| Progressive disease | 1 | 0 |
Analysis population for the primary outcome, as defined in the registry: No participants in the "Arm A" Group were assessed for the "Patients with TEAE related to Lenalidomide only" row, since they did not receive Lenalidomide.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Arm A | Arm B | Total |
|---|---|---|---|---|
| Participants analysed | 33 | 33 | 66 | |
| Age, Continuous | years | 63.8 (SD 11.64) | 61.4 (SD 12.34) | 62.6 (SD 11.96) |
| Age, Customized: 18-64 years | Participants | 16 | 17 | 33 |
| Age, Customized: 65-84 years | Participants | 16 | 16 | 32 |
| Age, Customized: Greater than or equal to 85 years | Participants | 1 | 0 | 1 |
| Sex: Female, Male: Female | Participants | 18 | 20 | 38 |
| Sex: Female, Male: Male | Participants | 15 | 13 | 28 |
| Race/Ethnicity, Customized: White | Participants | 31 | 33 | 64 |
| Race/Ethnicity, Customized: Other | Participants | 1 | 0 | 1 |
| Race/Ethnicity, Customized: Not Reported | Participants | 1 | 0 | 1 |
| Weight at Baseline (kg) | kg | 73.03 (SD 16.375) | 77.27 (SD 16.016) | 75.15 (SD 16.213) |
6. Primary Endpoint
The registry lists the primary outcome as Incidence and Severity of Treatment-emergent Adverse Events (TEAEs), measured over 6 months approximately.
| Element | Registry entry |
|---|---|
| Result type | Count Of Participants |
| Measure of spread | not applicable |
| Unit | Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is the incidence and severity of treatment-emergent adverse events, expressed as the number of participants with events. The reported timeframe is approximately 6 months. A TEAE is an adverse event arising after treatment begins; the label describes timing, not whether the treatment caused the event. Attribution to treatment and seriousness are distinct classifications, and event counts alone do not establish causation.
Counting participants with events is a direct way to describe how many people experienced a recorded safety event in each group. Separating serious from other adverse events can help characterize the types of safety observations recorded. In this registry record, 14 participants in Arm A and 17 in Arm B are listed with serious events; 31 in Arm A and 32 in Arm B are listed with other events. These figures describe the posted counts, not severity grades for every individual event. The record does not provide detailed definitions, grading criteria, or participant-level event histories.
Safety endpoints are particularly relevant in an early-phase study that assesses a treatment regimen and its tolerability. However, counts need context: the number of participants under observation, how long they were followed, how events were defined and attributed, and whether follow-up was complete. The approximate timeframe is reported, but further detail on event collection and missing observations is not reported in the registry record. The endpoint supports a descriptive account of safety; by itself it cannot answer whether one regimen is safer or establish a causal effect.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted safety results give counts of participants with serious and other adverse events in each arm. For serious events, the record lists 14 participants at risk and affected in Arm A’s affected count, with 33 at risk, and 17 affected with 33 at risk in Arm B. For other adverse events, 31 participants were affected among 33 at risk in Arm A, and 32 among 33 at risk in Arm B. These results are descriptive. No confidence intervals, p-values, or adjusted comparisons between arms are reported in the registry record.
The counts should not be read as proof that either regimen caused a particular event or as evidence that one treatment group has a reliably different safety profile. Random assignment is a design feature, but conclusions about group differences require a defined analysis and uncertainty estimates. Those analyses are not posted in the registry record. The study is identified as Phase Ib and aimed to assess safety and preliminary efficacy; the listed results do not supply a definitive comparative efficacy finding.
The record names febrile neutropenia as a listed serious-event term at 15.2%. Other listed serious-event terms are neutropenia, syncope, pyrexia, pulmonary embolism, and hypotension, each at 6.1%. These percentages should be interpreted according to the registry’s event reporting, not as estimates of an overall treatment effect. The record does not specify enough detail to infer whether events overlap within participants, how repeated events were handled, or whether the percentages use the same denominator in every case.
There were 4 deaths listed for Arm A and 2 for Arm B. The record does not establish from these counts whether deaths were related to treatment, due to lymphoma, or due to other causes. Death counts alone cannot be interpreted as a treatment comparison, particularly without follow-up context, cause and attribution, and an analysis that accounts for observation time.
The outcome list includes objective response rate, metabolic PET-negative complete response, progression-free survival, event-free survival, and time to next anti-lymphoma treatment. The registry record does not report results for these outcomes in the available analysis information. A listed outcome is not the same as a reported estimate. Consequently, the results support a narrow reading of posted safety counts, not a conclusion about efficacy or the comparative balance of benefits and harms.
9. Statistical Methods Explained
Randomization assigns participants to treatment groups by a chance-based process. In general, this can reduce systematic differences between groups at the start of a study, though chance imbalances can remain. A randomized design strengthens the basis for a comparison only when the analysis, outcome definitions, and handling of follow-up are also clear. This study is described as randomized and parallel, but the registry record does not report the randomization method, allocation concealment, or a detailed analysis plan. Open-label means masking was absent; expectations and knowledge of treatment can influence some aspects of event reporting or assessment, depending on how outcomes are collected.
What do the event counts tell us?
A participant count records how many people experienced at least one event in a defined category. It is different from a count of all event episodes: one participant may experience more than one event, while still contributing only once to a participant-level count. The primary endpoint is specified in participant counts. The registry record lists group sizes at risk and affected counts for serious and other events, but does not fully describe how multiple events per participant were consolidated or how severity was assigned. This limits what can be inferred from the counts beyond the recorded number of participants.
For a general comparison of two event proportions, an analysis can estimate the difference between groups and quantify uncertainty with a confidence interval. A confidence interval expresses a range of values compatible with the observed data under the analysis assumptions; it is not a guarantee that the true value lies within that range. A hypothesis test can assess how compatible the data are with a specified null hypothesis. Neither an interval nor a test is reported for the primary endpoint in the registry record, so the counts should not be treated as a statistically established difference. No new comparison can be reconstructed from the posted summaries without making additional assumptions.
Why does the denominator matter?
Event counts are easier to interpret when the number of participants at risk and the period of observation are known. The registry lists 33 at risk in each arm for serious and other events, and gives an approximate 6-month primary-outcome timeframe. Equal listed group sizes do not ensure equal time under observation for every participant. If follow-up duration varies, simple participant counts may not capture differences in exposure time. Time-to-event methods can account for varying follow-up in suitable settings, but the record does not describe an analysis of time to first adverse event or provide exposure-adjusted rates.
Severity and seriousness are also different ideas. Seriousness generally refers to regulatory or clinical criteria such as outcomes that meet a formal serious-event definition; severity describes how intense an event is. The endpoint title includes incidence and severity, and the registry reports serious and other event counts, but detailed grading criteria and distributions by severity are not reported in the registry record. The listed serious-event terms should therefore not be taken as a complete account of all safety outcomes.
What do the planning assumptions mean?
General sample-size planning uses assumptions about the effect worth detecting, the statistical significance threshold, allocation, and the analysis method. The planning illustration associated with these results is described as based on the observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation; it considers a stated fraction of the observed effect. Such planning calculations are not the trial’s own sample-size justification unless the record says so. The justification is not reported in the registry record. These illustrations are planning aids, not observed power and not evidence that the study had a particular probability of detecting an effect.
Normal approximations are general methods that use a mathematical distribution to estimate uncertainty or plan sample sizes. Their suitability depends on the outcome, sample size, event frequency, and assumptions. Sparse outcomes or small groups can make approximations less reliable, so exact or alternative methods may sometimes be considered. The registry record does not identify an inferential method used for the posted safety counts. No recalculated comparative result is available to interpret, and there is no sponsor analysis to compare with a recalculation.
For time-to-event outcomes such as progression-free survival, methods commonly account for the time until an event and for participants whose event status is not observed by the end of follow-up. The registry lists such outcomes at specified time points, but does not report estimates, censoring details, or analysis methods. General descriptions of these methods cannot substitute for the absent study-specific results.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 11 outcome measures, including several response, safety, and time-to-event outcomes. When a study assesses multiple outcomes or several time points, the chance of at least one apparently notable result can increase if each is tested separately. Statistical plans may address this through a prespecified primary outcome, a testing hierarchy, or an adjustment for multiple comparisons. The registry record does not report a multiplicity strategy or enough analysis detail to determine whether one was used. The primary endpoint is identified as TEAEs, but the posted record does not provide comparative tests for that endpoint.
The registry record reports 0 analyses in its analysis information. It does not provide analysis populations, such as whether results were based on all randomized participants, treated participants, or another defined group. The safety counts list 33 participants at risk in each arm, but that alone does not define the population used for every outcome or establish that all enrolled participants were included in every analysis.
Missing outcome data can affect estimates when participants have incomplete follow-up or outcomes are not recorded. The record does not describe missing-data amounts, reasons for missingness, imputation, censoring, or sensitivity analyses. The primary outcome timeframe is approximately 6 months, but follow-up completeness is not reported in the registry record. Interim analyses and any stopping rules are also not reported in the registry record. Without these details, readers cannot assess whether missing observations or repeated analyses influenced the reported results.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Arm A | 14 | 33 | 42.4% |
| Arm B | 17 | 33 | 51.5% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Arm A | 4 of 33 |
| Arm B | 2 of 33 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Arm A | 31 of 33 |
| Arm B | 32 of 33 |
Most frequent serious adverse event terms
| Event term | Organ system | Arm A | Arm B |
|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders | 5 of 33 | 5 of 33 |
| Neutropenia | Blood and lymphatic system disorders | 2 of 33 | 2 of 33 |
| Pyrexia | General disorders | 1 of 33 | 2 of 33 |
| Syncope | Nervous system disorders | 0 of 33 | 2 of 33 |
| Urinary tract infection | Infections and infestations | 1 of 33 | 1 of 33 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 2 of 33 | 0 of 33 |
| Hypotension | Vascular disorders | 0 of 33 | 2 of 33 |
| Anaemia | Blood and lymphatic system disorders | 1 of 33 | 0 of 33 |
| Thrombocytopenia | Blood and lymphatic system disorders | 1 of 33 | 0 of 33 |
| Abdominal pain | Gastrointestinal disorders | 0 of 33 | 1 of 33 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Arm A | Arm B |
|---|---|---|---|
| Neutropenia | Blood and lymphatic system disorders | 18 of 33 | 26 of 33 |
| Anaemia | Blood and lymphatic system disorders | 16 of 33 | 20 of 33 |
| Diarrhoea | Gastrointestinal disorders | 10 of 33 | 11 of 33 |
| Thrombocytopenia | Blood and lymphatic system disorders | 6 of 33 | 14 of 33 |
| Leukopenia | Blood and lymphatic system disorders | 10 of 33 | 9 of 33 |
| Nausea | Gastrointestinal disorders | 10 of 33 | 9 of 33 |
| Neuropathy peripheral | Nervous system disorders | 9 of 33 | 10 of 33 |
| Constipation | Gastrointestinal disorders | 10 of 33 | 8 of 33 |
| Fatigue | General disorders | 11 of 33 | 5 of 33 |
| Hypokalaemia | Metabolism and nutrition disorders | 7 of 33 | 9 of 33 |
Serious events with the highest arm-level rate: febrile neutropenia (15.2%), neutropenia (6.1%), syncope (6.1%), pyrexia (6.1%), pulmonary embolism (6.1%).
The safety counts distinguish participants with serious events from participants with other adverse events. In Arm A, 14 of 33 participants are listed as affected by serious events and 31 of 33 by other events. In Arm B, 17 of 33 are listed with serious events and 32 of 33 with other events. The registry record’s wording identifies participants, so these numbers should not be interpreted as the total number of event episodes.
The listed serious-event terms include febrile neutropenia at 15.2%, and neutropenia, syncope, pyrexia, pulmonary embolism, and hypotension at 6.1% each. The record does not report details needed to determine overlap among terms, recurrence, or the distribution of event severity. Those percentages should be read as registry-listed event information rather than as a basis for a direct between-arm comparison.
Deaths are listed as 4 in Arm A and 2 in Arm B. The record does not specify the cause or treatment attribution for those deaths in the reported information. A death count is not, on its own, a cause-specific safety outcome or a comparative risk estimate. Neither the adverse-event counts nor the death counts establish that treatment caused an event or explain how risk may differ over time.
12. What the Result Does, and Does Not, Mean
The registry record describes a randomized early-phase study of two regimens built on R-CHOP: tafasitamab plus R-CHOP, and tafasitamab plus lenalidomide plus R-CHOP. Its primary outcome concerns the incidence and severity of treatment-emergent adverse events over approximately 6 months. The posted safety information gives participant counts for serious and other adverse events, along with selected serious-event terms and death counts.
These data provide a descriptive account of events recorded in the two groups. They do not establish that any listed event was caused by treatment, and they do not demonstrate that the event experience differed reliably between groups. The registry record does not report comparative uncertainty estimates or statistical tests for these counts. Treatment assignment was unmasked, which is relevant context when interpreting outcomes that may depend on event recognition, reporting, or assessment.
The record’s stated aim includes preliminary efficacy, and it lists outcomes such as objective response, complete response, progression-free survival, event-free survival, and time to next anti-lymphoma treatment. Those outcomes are not accompanied by posted comparative estimates in the analysis information. Therefore, the outcome list should not be read as a result, and the safety counts cannot answer whether either regimen is more effective.
The findings also cannot be generalized automatically to people outside the study population or to other treatment settings. The registry describes adults with newly diagnosed, previously untreated DLBCL; further eligibility and participant characteristics are not included in the reported information. The overall meaning is consequently limited: the record documents a completed Phase Ib randomized study and reports selected safety counts, but it does not support a definitive comparative claim about safety or efficacy.
13. Why This Trial Matters Statistically
This trial is statistically notable because it compares two related multidrug regimens in a randomized, parallel-group design while focusing on safety and preliminary efficacy. The distinction between descriptive counts and comparative evidence is especially important in a small early-phase study. Counts can show what the registry recorded, but reliable conclusions about differences require an analysis that quantifies uncertainty and clarifies how participants and events were handled.
The primary endpoint is participant-based, while the record also lists outcomes that may require different methods, including response measures and time-to-event outcomes. Each outcome type raises different questions about definitions, follow-up, missing observations, and analysis populations. A list of many outcomes can make multiplicity and selective emphasis relevant concerns, yet the registry record does not report how these issues were addressed.
The two arms share R-CHOP and tafasitamab, with lenalidomide added in Arm B. A comparison between them would therefore concern the regimens as assigned, not the isolated biological effect of one component under otherwise identical conditions unless the analysis and design support that interpretation. The record does not report a comparative efficacy analysis, so the listed outcomes cannot establish an added effect of lenalidomide or any other component.
For readers assessing trial evidence, this record illustrates why registration details and outcome names must be separated from statistical results. Randomization, completion status, participant counts, endpoint definitions, uncertainty estimates, and analysis transparency all contribute to interpretation. Here, the available safety counts are useful descriptive information, while the absence of posted analyses leaves important comparative questions unresolved.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The registry record contains limited detail for interpreting the safety results. It specifies an approximate 6-month timeframe and participant counts, but does not report event definitions, grading criteria, event attribution, event-level detail, follow-up completeness, or how recurrent events were handled. The listed serious-event terms and percentages do not establish whether individual participants experienced more than one term.
The study was open-label, with no masking. The record does not describe blinded assessment procedures for any outcomes. This matters particularly for outcomes whose recognition or classification may involve judgment. The randomization procedure and allocation concealment are also not reported in the registry record, so those aspects cannot be evaluated from the available description.
Although the trial is completed and the registry lists an enrollment of 66, it does not report participant flow, withdrawals, exclusions, or the populations used in individual analyses. The analysis information reports 0 analyses. No comparative estimates, confidence intervals, p-values, efficacy results, missing-data methods, or sensitivity analyses are reported in the registry record. The sample-size justification and any interim-analysis procedures are also not reported.
The reported counts do not give enough information to infer event rates over person-time, causal attribution, or the reasons for deaths. The record also lists several secondary outcomes without corresponding posted results in the analysis information. As a result, this account is limited to the design description and the reported safety counts; it cannot resolve comparative safety or efficacy.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL — NCT04134936.
- Registry record last updated 2024-10-16; status last verified 2024-10.
- Results first posted 2024-10-16.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT04134936, First-MIND, was a completed Phase Ib, randomized, open-label, multicentre, parallel-group study sponsored by MorphoSys AG. It enrolled adults with newly diagnosed, previously untreated DLBCL. The two groups received tafasitamab plus R-CHOP, or tafasitamab plus lenalidomide plus R-CHOP. Enrollment was 66; the reported safety groups each list 33 participants at risk.
The primary outcome was incidence and severity of TEAEs, measured as participant counts over approximately 6 months. The registry lists serious and other adverse-event counts, selected serious-event terms, and deaths. It also lists response and time-to-event outcomes, but comparative efficacy analyses are not reported in the registry record. The record does not report a detailed statistical analysis plan, analysis populations, missing-data methods, or multiplicity procedures.